Compugen (CGEN) Competitors $1.64 -0.02 (-1.20%) Closing price 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.30%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEN vs. TSHA, BCYC, MNMD, DNTH, KURA, MRVI, RLAY, VECT, KROS, and ARVNShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Taysha Gene Therapies (TSHA), Bicycle Therapeutics (BCYC), Mind Medicine (MindMed) (MNMD), Dianthus Therapeutics (DNTH), Kura Oncology (KURA), Maravai LifeSciences (MRVI), Relay Therapeutics (RLAY), VectivBio (VECT), Keros Therapeutics (KROS), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry. Compugen vs. Its Competitors Taysha Gene Therapies Bicycle Therapeutics Mind Medicine (MindMed) Dianthus Therapeutics Kura Oncology Maravai LifeSciences Relay Therapeutics VectivBio Keros Therapeutics Arvinas Taysha Gene Therapies (NASDAQ:TSHA) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk. Does the MarketBeat Community prefer TSHA or CGEN? Compugen received 192 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 79.05% of users gave Taysha Gene Therapies an outperform vote while only 64.24% of users gave Compugen an outperform vote. CompanyUnderperformOutperformTaysha Gene TherapiesOutperform Votes11779.05% Underperform Votes3120.95% CompugenOutperform Votes30964.24% Underperform Votes17235.76% Does the media favor TSHA or CGEN? In the previous week, Taysha Gene Therapies had 10 more articles in the media than Compugen. MarketBeat recorded 13 mentions for Taysha Gene Therapies and 3 mentions for Compugen. Compugen's average media sentiment score of 1.23 beat Taysha Gene Therapies' score of 0.89 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compugen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in TSHA or CGEN? 77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, TSHA or CGEN? Taysha Gene Therapies has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500. Is TSHA or CGEN more profitable? Compugen has a net margin of 2.67% compared to Taysha Gene Therapies' net margin of -229.67%. Compugen's return on equity of 2.62% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-229.67% -106.36% -49.16% Compugen 2.67%2.62%1.36% Which has better earnings and valuation, TSHA or CGEN? Compugen has higher revenue and earnings than Taysha Gene Therapies. Compugen is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$7.22M75.48-$111.57M-$0.34-7.47Compugen$27.59M5.30-$18.75M-$0.16-10.25 Do analysts prefer TSHA or CGEN? Taysha Gene Therapies presently has a consensus price target of $7.57, suggesting a potential upside of 198.09%. Compugen has a consensus price target of $4.00, suggesting a potential upside of 143.90%. Given Taysha Gene Therapies' higher possible upside, equities analysts plainly believe Taysha Gene Therapies is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCompugen beats Taysha Gene Therapies on 11 of the 17 factors compared between the two stocks. Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$146.35M$3.09B$5.58B$8.50BDividend YieldN/A1.56%5.28%4.17%P/E Ratio82.0032.6627.1919.64Price / Sales5.30455.28408.78152.17Price / CashN/A168.6838.3234.64Price / Book2.253.366.974.60Net Income-$18.75M-$72.35M$3.23B$248.06M7 Day Performance-5.75%0.32%-0.88%-1.02%1 Month Performance21.48%17.21%7.81%3.51%1 Year Performance-20.00%-17.83%31.53%12.68% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen2.228 of 5 stars$1.64-1.2%$4.00+143.9%-18.6%$146.35M$27.59M82.0070Positive NewsTSHATaysha Gene Therapies3.836 of 5 stars$2.80-1.4%$7.57+170.4%-32.2%$601.05M$7.22M4.44180Analyst ForecastAnalyst RevisionGap DownBCYCBicycle Therapeutics3.3545 of 5 stars$8.54-0.1%$25.00+192.7%-64.5%$591.43M$25.72M-2.60240News CoverageAnalyst RevisionMNMDMind Medicine (MindMed)1.9298 of 5 stars$7.76-0.4%$25.50+228.6%-7.0%$588.56MN/A-3.4340Positive NewsAnalyst RevisionGap DownDNTHDianthus Therapeutics1.387 of 5 stars$18.19-3.5%$53.00+191.4%-23.3%$584.99M$6.52M-7.2880Analyst RevisionKURAKura Oncology4.3493 of 5 stars$6.73flat$24.50+264.0%-69.3%$582.65M$67.99M-2.85130Analyst RevisionMRVIMaravai LifeSciences4.0318 of 5 stars$2.28-4.6%$6.64+191.2%-71.3%$580.63M$241.86M-1.39610Options VolumeRLAYRelay Therapeutics2.2058 of 5 stars$3.36flat$17.67+425.8%-56.0%$576.06M$7.68M-1.29330Gap DownVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeKROSKeros Therapeutics3.6341 of 5 stars$14.09-6.3%$37.00+162.6%-72.2%$572.27M$214.71M-2.70100Analyst DowngradeHigh Trading VolumeARVNArvinas3.867 of 5 stars$7.83+4.0%$20.29+159.1%-71.4%$571.52M$426.90M-2.83420Analyst RevisionGap DownHigh Trading Volume Related Companies and Tools Related Companies Taysha Gene Therapies Alternatives Bicycle Therapeutics Alternatives Mind Medicine (MindMed) Alternatives Dianthus Therapeutics Alternatives Kura Oncology Alternatives Maravai LifeSciences Alternatives Relay Therapeutics Alternatives VectivBio Alternatives Keros Therapeutics Alternatives Arvinas Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEN) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGEN Stock Free CGEN Stock Alerts